Bone Biologics Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
| Nine months Ended September 30, 2024 · Nine months Ended September 30, 2023 | ||||
|---|---|---|---|---|
| (unaudited) · (unaudited) | ||||
| Cash flows from operating activities | ||||
| Net loss | $(2,590,705) | $(7,398,846) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 88,065 | 81,460 | ||
| Change in fair value of warrant liability | (38,122) | (867,930) | ||
| Changes in operating assets and liabilities: | ||||
| Advances on research and development contract services | (56,898) | 170,205 | ||
| Prepaid insurance and prepaid expenses | 268,700 | 262,962 | ||
| Accounts payable and accrued expenses | (93,205) | 42,859 | ||
| Research and development contract liabilities | 65,716 | 171,401 | ||
| Accrued legal settlement | (414,989) | - | ||
| Net cash used in operating activities | (2,771,438) | (7,537,889) | ||
| Cash flows from financing activities | ||||
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 1,504,113 | 4,452,163 | ||
| Exercise of pre-funded warrants | 662 | - | ||
| Proceeds from issuance of common shares from warrant inducement, net of costs | 1,806,520 | - | ||
| Net cash provided by financing activities | 3,311,295 | 4,452,163 | ||
| Net increase (decrease) in cash | 539,857 | (3,085,726) | ||
| Cash, beginning of period | 3,026,569 | 7,538,312 | ||
| Cash, end of period | $3,566,426 | $4,452,586 | ||
| Supplemental information | ||||
| Income taxes paid | $ | - | $ | - |
| Noncash investing and financing activities | ||||
| Options issued to settle accrued bonus | $77,400 | - | ||
| Deemed dividend – warrant inducement | $3,212,504 | - | ||
| Extinguishment of warrant liability upon exercise of warrants | - | 711,024 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.